Plain-English translation of NCT05442515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing CD19/CD22 bicistronic CAR T cells, a new type of engineered immune cell therapy for children and young adults with blood cancers (leukemia and lymphoma) that have returned or stopped responding to standard chemotherapy. The treatment involves taking your own immune cells, engineering them in a lab to recognize and attack cancer cells, and then putting them back into your body. This new version targets two cancer markers at once, which researchers hope will work better than earlier versions.
Some patients' cancers come back or stop responding even after receiving similar CAR T cell therapies. Researchers found that cancer cells sometimes hide by turning off one of the two markers that current treatments target. This trial is testing a new medication that targets both markers simultaneously, which may prevent cancer cells from escaping and help the treatment work longer.
You likely qualify if…
You likely don't qualify if…
You will first receive conditioning chemotherapy to prepare your body for the new cells. Your own T cells (a type of immune cell) will be collected, sent to a laboratory where they are engineered to recognize your cancer, and then returned to you as an infusion. You'll be closely monitored during and after the treatment, with frequent hospital visits or clinic appointments to check for side effects and whether the treatment is working. The study will track your health and cancer status over time to see how well the new treatment works.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States